CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Market share analysis, 2016
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of rare diseases and various life-threatening conditions
3.4.1.2. Increase in demand for albumin
3.4.1.3. Growing preferences for recombinant albumin
3.4.1.4. Rise in non-therapeutic application of albumin

3.4.2. Restraints

3.4.2.1. Stringent government regulations
3.4.2.2. Risks associated with albumin

3.4.3. Opportunities

3.4.3.1. Opportunities in emerging economies
3.4.3.2. Development of cost effective therapeutics through large scale production

3.4.4. Impact analyses

3.5. Government regulations
3.6. Patent analysis (2013-2018)

3.6.1. Patent analysis, by year
3.6.2. Patent analysis for year 2017, by country

CHAPTER 4: ALBUMIN MARKET, BY PRODUCT

4.1. Overview

4.1.1. Market size and forecast

4.2. Human serum albumin

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Bovine serum albumin

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Recombinant albumin

4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

CHAPTER 5: ALBUMIN MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast (value)

5.2. Therapeutics

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Drug formulation & vaccines

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Component of media

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

5.5. Other applications

5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country

CHAPTER 6: ALBUMIN MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America albumin market, by country

6.2.2.1. U.S.

6.2.2.1.1. Market size and forecast, by product
6.2.2.1.2. Market size and forecast, by application

6.2.2.2. Canada

6.2.2.2.1. Market size and forecast, by product
6.2.2.2.2. Market size and forecast, by application

6.2.2.3. Mexico

6.2.2.3.1. Market size and forecast, by product
6.2.2.3.2. Market size and forecast, by application

6.2.3. North America market size and forecast, by product
6.2.4. North America market size and forecast, by application

6.3. Europe

6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe market size and forecast, by country

6.3.2.1. Germany

6.3.2.1.1. Market size and forecast, by product
6.3.2.1.2. Market size and forecast, by application

6.3.2.2. France

6.3.2.2.1. Market size and forecast, by product
6.3.2.2.2. Market size and forecast, by application

6.3.2.3. UK

6.3.2.3.1. Market size and forecast, by product
6.3.2.3.2. Market size and forecast, by application

6.3.2.4. Italy

6.3.2.4.1. Market size and forecast, by product
6.3.2.4.2. Market size and forecast, by application

6.3.2.5. Spain

6.3.2.5.1. Market size and forecast, by product
6.3.2.5.2. Market size and forecast, by application

6.3.2.6. Rest of Europe

6.3.2.6.1. Market size and forecast, by product
6.3.2.6.2. Market size and forecast, by application
6.3.2.6.3. Europe market size and forecast, by product
6.3.2.6.4. Europe market size and forecast, by application

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors and opportunities
6.4.2. Asia-Pacific market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Market size and forecast, by product
6.4.2.1.2. Market size and forecast, by application

6.4.2.2. China

6.4.2.2.1. Market size and forecast, by product
6.4.2.2.2. Market size and forecast, by application

6.4.2.3. India

6.4.2.3.1. Market size and forecast, by product
6.4.2.3.2. Market size and forecast, by application

6.4.2.4. Australia

6.4.2.4.1. Market size and forecast, by product
6.4.2.4.2. Market size and forecast, by application

6.4.2.5. South Korea

6.4.2.5.1. Market size and forecast, by product
6.4.2.5.2. Market size and forecast, by application

6.4.2.6. Rest of Asia-Pacific

6.4.2.6.1. Market size and forecast, by product
6.4.2.6.2. Market size and forecast, by application

6.4.3. Asia-Pacific market size and forecast, by product
6.4.4. Asia-Pacific market size and forecast, by application

6.5. LAMEA

6.5.1. Key market trends, growth factors and opportunities
6.5.2. LAMEA market size and forecast, by country

6.5.2.1. Brazil

6.5.2.1.1. Market size and forecast, by product
6.5.2.1.2. Market size and forecast, by application

6.5.2.2. Saudi Arabia

6.5.2.2.1. Market size and forecast, by product
6.5.2.2.2. Market size and forecast, by application

6.5.2.3. South Africa

6.5.2.3.1. Market size and forecast, by type
6.5.2.3.2. Market size and forecast, by application

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Market size and forecast, by product
6.5.2.4.2. Market size and forecast, by application

6.5.3. LAMEA market size and forecast, by product
6.5.4. LAMEA market size and forecast, by application

CHAPTER 7: COMPANY PROFILES

7.1. Baxter International Inc.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance

7.2. China Biologic Products Holdings, Inc.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance

7.3. CSL Limited

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance

7.4. Grifols S.A. (Grifols International, S.A.)

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. Merck KGaA

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. Novozymes A/S (Albumedix Ltd.)

7.6.1. Company overview
7.6.2. Operating business segments
7.6.3. Product portfolio
7.6.4. Business performance

7.7. Octapharma AG

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance

7.8. Shire Plc. (Shire US, Inc.)

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. Thermo Fisher Scientific Inc (Affymetrix, Inc.)

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. Ventria Bioscience

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating product categories
7.10.4. Product portfolio

LIST OF TABLES

TABLE 01. MARKETED FORMULATION OF ALBUMIN
TABLE 02. GLOBAL ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 03. HUMAN SERUM ALBUMIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 04. BOVINE SERUM ALBUMIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 05. RECOMBINANT ALBUMIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 06. GLOBAL ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 07. ALBUMIN MARKET FOR THERAPEUTICS, BY REGION, 2016-2023 ($MILLION)
TABLE 08. ALBUMIN MARKET FOR DRUG FORMULATION & VACCINES, BY REGION, 2016-2023 ($MILLION)
TABLE 09. ALBUMIN MARKET FOR COMPONENT OF MEDIA, BY REGION, 2016-2023 ($MILLION)
TABLE 10. ALBUMIN MARKET FOR OTHER APPLICATIONS, BY REGION, 2016-2023 ($MILLION)
TABLE 11. ALBUMIN MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 12. NORTH AMERICA ALBUMIN MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 13. U.S. ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 14. U.S. ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 15. CANADA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 16. CANADA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 17. MEXICO ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 18. MEXICO ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 19. NORTH AMERICA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 20. NORTH AMERICA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 21. EUROPE ALBUMIN MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 22. GERMANY ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 23. GERMANY ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 24. FRANCE ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 25. FRANCE ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 26. UK ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 27. UK ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 28. ITALY ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 29. ITALY ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 30. SPAIN ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 31. SPAIN ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 32. REST OF EUROPE ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 33. REST OF EUROPE ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 34. EUROPE ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 35. EUROPE ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 36. ASIA-PACIFIC ALBUMIN MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 37. JAPAN ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 38. JAPAN ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 39. CHINA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 40. CHINA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 41. INDIA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 42. INDIA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 43. AUSTRALIA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 44. AUSTRALIA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 45. SOUTH KOREA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 46. SOUTH KOREA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 47. REST OF ASIA-PACIFIC ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 48. REST OF ASIA-PACIFIC ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 49. ASIA-PACIFIC ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 50. ASIA-PACIFIC ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 51. LAMEA ALBUMIN MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 52. BRAZIL ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 53. BRAZIL ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 54. SAUDI ARABIA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 55. SAUDI ARABIA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 56. SOUTH AFRICA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 57. SOUTH AFRICA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 58. REST OF LAMEA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 59. REST OF LAMEA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 60. LAMEA ALBUMIN MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 61. LAMEA ALBUMIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 62. BAXTER: COMPANY SNAPSHOT
TABLE 63. BAXTER: OPERATING SEGMENTS
TABLE 64. BAXTER: PRODUCT PORTFOLIO
TABLE 65. CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.: COMPANY SNAPSHOT
TABLE 66. CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.: PRODUCT PORTFOLIO
TABLE 67. CSL: COMPANY SNAPSHOT
TABLE 68. CSL: PRODUCT SEGMENTS
TABLE 69. CSL: PRODUCT PORTFOLIO
TABLE 70. GRIFOLS: COMPANY SNAPSHOT
TABLE 71. GRIFOLS: OPERATING SEGMENTS
TABLE 72. GRIFOLS: PRODUCT PORTFOLIO
TABLE 73. MERCK: COMPANY SNAPSHOT
TABLE 74. MERCK: PRODUCT SEGMENTS
TABLE 75. MERCK: PRODUCT PORTFOLIO
TABLE 76. NOVOZYMES A/S: COMPANY SNAPSHOT
TABLE 77. NOVOZYMES A/S: PRODUCT CATEGORIES
TABLE 78. NOVOZYMES A/S: PRODUCT PORTFOLIO
TABLE 79. OCTAPHARMA: COMPANY SNAPSHOT
TABLE 80. OCTAPHARMA: PRODUCT SEGMENTS
TABLE 81. OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 82. SHIRE: COMPANY SNAPSHOT
TABLE 83. SHIRE: PRODUCT PORTFOLIO
TABLE 84. THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT
TABLE 85. THERMO FISHER SCIENTIFIC INC: OPERATING SEGMENTS
TABLE 86. THERMO FISHER SCIENTIFIC INC: PRODUCT PORTFOLIO
TABLE 87. VENTRIA: COMPANY SNAPSHOT
TABLE 88. VENTRIA: PRODUCT CATEGORIES
TABLE 89. VENTRIA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. ALBUMIN MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MARKET SHARE ANALYSIS, 2016
FIGURE 04. AGE DISTRIBUTION OF BURN PATIENTS BY GENDER IN INDIA, 2013 (IN PERCENTAGE)
FIGURE 05. IMPACT ANALYSES
FIGURE 06. PATENTS REGISTERED/APPROVED IN THE WORLD, 2013-2018
FIGURE 07. PATENTS ANALYSIS BY YEAR, 2013 THROUGH 2018
FIGURE 08. YEAR 2017 PATENT ANALYSIS, BY COUNTRY
FIGURE 09. COMPARATIVE ANALYSIS OF HUMAN SERUM MARKET, 2016-2023 ($MILLION)
FIGURE 10. COMPARATIVE ANALYSIS OF BOVINE SERUM ALBUMIN MARKET, 2016-2023 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF RECOMBINANT ALBUMIN MARKET, 2016 & 2023 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF ALBUMIN MARKET FOR THERAPEUTICS, 2016-2023 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF ALBUMIN MARKET FOR DRUG FORMULATION & VACCINES,
2016 & 2023 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF ALBUMIN MARKET FOR COMPONENT OF MEDIA, 2016 & 2023 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF ALBUMIN MARKET FOR OTHER APPLICATIONS, 2016 & 2023 ($MILLION)
FIGURE 16. NUMBER OF CARDIOVASCULAR SURGERIES IN CANADA FROM 2007 TO 2014
FIGURE 17. INCIDENCE RATE OF DIFFERENT TYPES CANCER IN GERMANY 2012
FIGURE 18. NUMBER OF ORGANS TRANSPLANTED IN CHINA FROM 2010 TO 2015
FIGURE 19. BAXTER: NET SALES, 2015-2017 ($MILLION)
FIGURE 20. BAXTER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 21. BAXTER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 22. CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.: REVENUE, 2015-2017 ($MILLION)
FIGURE 23. CSL: NET SALES, 2015-2017 ($MILLION)
FIGURE 24. CSL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 25. CSL: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 26. GRIFOLS: REVENUE, 2015-2017 ($MILLION)
FIGURE 27. GRIFOLS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 28. GRIFOLS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 29. MERCK: NET SALES, 2015-2017 ($MILLION)
FIGURE 30. MERCK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 31. MERCK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 32. NOVOZYMES A/S: REVENUE, 2015-2017 ($MILLION)
FIGURE 33. NOVOZYMES A/S: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 34. NOVOZYMES A/S: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 35. OCTAPHARMA: NET SALES, 2015-2017 ($MILLION)
FIGURE 36. SHIRE: NET SALES, 2015-2017 ($MILLION)
FIGURE 37. SHIRE: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 38. SHIRE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 39. THERMO FISHER SCIENTIFIC INC: REVENUE, 2015-2017 ($MILLION)
FIGURE 40. THERMO FISHER SCIENTIFIC INC: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. THERMO FISHER SCIENTIFIC INC: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

Albumin is the most abundant plasma protein, constituting approximately 50% of total plasma protein. It is produced in the liver and maintains oncotic pressure of blood, and transports hormones, fatty acids, and other compounds. It is obtained from human and animal’s plasma by fractionation that is further used to treat different disorders.

Rise in number of patients suffering from life-threatening diseases and conditions, especially hypoalbuminemia, is the major factor that drives the growth of the global albumin market. Other factors such as increase in demand for albumin products, rise in non-therapeutic application of albumin, and surge in preferences for recombinant albumin products usage in various treatments are expected to have a significant impact on the growth of the market. However, factors such as stringent governmental regulations and post-operative risks associated with donated albumin hamper the market growth.

The use of albumin is the highest in North America, owing to the presence of large patient population and high adoption of recombinant albumin, followed by Europe and Asia-Pacific. In addition, albumin providers and distributors have focused on expanding their presence in the emerging economies, which in turn is anticipated to drive the market growth.